Logo of EBR Systems (ASX:EBR)Latest EBR Systems (ASX:EBR) News

Page 2
Page 2 of 6

Healthcare Wrap - Week 38 (14 Sept -> 18 Sept) 2026

AdAlta led the healthcare board after a US cell-therapy manufacturing deal gave its automation platform commercial credibility, while Vectus fell despite reporting a profit. Clinical trial updates, diagnostic launches and fresh funding plans kept the sector active.
Logan Eniac
19 Sept 2026

EBR gains FDA alignment for WiSE safety labelling update

EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.
Victor Sage
16 Sept 2026

EBR’s New Facility Reaches FDA Inspection Stage Ahead of Year-End Decision

EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.
Victor Sage
15 Sept 2026

Healthcare Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Neurizon and Clever Culture Systems led the week with 35.71% gains, while CONNEQT also rose despite giving back part of its reopening move.
Biotech trial funding, device manufacturing and healthcare launches shaped investor decisions across the sector.
Logan Eniac
12 Sept 2026

FDA Clears EBR’s WiSE System of Recall After Cybersecurity Incident

The FDA has agreed that EBR Systems’ WiSE cardiac pacing system does not require a field corrective action or recall following a February cybersecurity incident. The device maker says it has found no evidence of any impact on the safety or performance of fielded systems, while remediation work continues.
Victor Sage
9 Sept 2026

EBR Systems Boosts WiSE Production with ISO-Certified Facility and FDA Approval in Sight

EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.
Ada Torres
7 Sept 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

EBR Systems Advances WiSE CRT Commercial Rollout with Major US Contracts and Capital Raise

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.
Ada Torres
12 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

EBR Systems Accelerates WiSE Adoption with 46 Implants and Major Contracts in Q2 2026

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.
Ada Torres
30 July 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

EBR Systems Rolls Out WiSE Coupler to Boost US Cardiac Implant Procedures

EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.
Ada Torres
24 July 2026